SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease - PubMed
4 hours ago
- #Alzheimer's disease
- #Stem cell therapy
- #Neuroinflammation
- SSEA3 and CD105 positivity in human neural crest-derived nasal turbinate stem cells (NTSCs) are linked to their therapeutic efficacy for Alzheimer's disease (AD).
- NTSCs with higher percentages of SSEA3+/CD105+ cells (NTSCs-H) showed greater proliferative capacity, multilineage differentiation potency, and secretion of neuroprotective cytokines compared to those with lower percentages (NTSCs-L).
- Both NTSCs-H and pure SSEA3+/CD105+ cells (NTSCs-SC) improved cognitive function, reduced Aβ deposition, inflammation, and neuronal death in AD model mice and cerebral organoids.
- No significant difference in therapeutic outcomes was observed between NTSCs-H and NTSCs-SC treatments.
- SSEA3/CD105 positivity could serve as a marker for predicting the therapeutic potential of NTSCs in AD treatment.